Cargando…

High expression of DLC family proteins predicts better prognosis and inhibits tumor progression in NSCLC

The incidence of primary lung cancer (PLC) is increasing and is becoming a leading cause of cancer-associated mortality worldwide. Non-small cell lung cancer (NSCLC) accounts for ~80% of PLC cases and has the worst prognosis among malignant tumors. Deleted in liver cancer (DLC) proteins belong to th...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Li, Sun, Jing, Song, Jun-Ding
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6522875/
https://www.ncbi.nlm.nih.gov/pubmed/31059015
http://dx.doi.org/10.3892/mmr.2019.10146
_version_ 1783419207540539392
author Sun, Li
Sun, Jing
Song, Jun-Ding
author_facet Sun, Li
Sun, Jing
Song, Jun-Ding
author_sort Sun, Li
collection PubMed
description The incidence of primary lung cancer (PLC) is increasing and is becoming a leading cause of cancer-associated mortality worldwide. Non-small cell lung cancer (NSCLC) accounts for ~80% of PLC cases and has the worst prognosis among malignant tumors. Deleted in liver cancer (DLC) proteins belong to the RhoGTPase-activating protein family and are considered to be tumor suppressor genes. However, the role of the proteins, particularly DLC2 and DLC3, in NSCLC, has not been fully elucidated. The present study investigated the expression levels and prognostic values of DLCs in NSCLC using The Cancer Genome Atlas, the Genotype-Tissue Expression project and Kaplan-Meier plotter datasets. The current study demonstrated that the three DLCs were downregulated in NSCLC. High expression levels of DLC1 and DLC2 were associated with an improved survival in NSCLC. Additionally, the effects of DLCs on the proliferation and apoptosis of the lung cancer cell line A-549 were investigated in vitro using a Cell Counting Kit-8 assay and flow cytometry analysis. DLC2 and DLC3 overexpression inhibited proliferation and induced apoptosis in A549 cells. To the best of our knowledge, the current study was the first to investigate the expression level and prognostic values of DLC2 and DLC3 in NSCLC. The results indicated that DLC1 DLC2 and DLC3 serve specific roles in the occurrence and development of NSCLC, and may be considered as potential prognostic indicators in NSCLC.
format Online
Article
Text
id pubmed-6522875
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-65228752019-06-18 High expression of DLC family proteins predicts better prognosis and inhibits tumor progression in NSCLC Sun, Li Sun, Jing Song, Jun-Ding Mol Med Rep Articles The incidence of primary lung cancer (PLC) is increasing and is becoming a leading cause of cancer-associated mortality worldwide. Non-small cell lung cancer (NSCLC) accounts for ~80% of PLC cases and has the worst prognosis among malignant tumors. Deleted in liver cancer (DLC) proteins belong to the RhoGTPase-activating protein family and are considered to be tumor suppressor genes. However, the role of the proteins, particularly DLC2 and DLC3, in NSCLC, has not been fully elucidated. The present study investigated the expression levels and prognostic values of DLCs in NSCLC using The Cancer Genome Atlas, the Genotype-Tissue Expression project and Kaplan-Meier plotter datasets. The current study demonstrated that the three DLCs were downregulated in NSCLC. High expression levels of DLC1 and DLC2 were associated with an improved survival in NSCLC. Additionally, the effects of DLCs on the proliferation and apoptosis of the lung cancer cell line A-549 were investigated in vitro using a Cell Counting Kit-8 assay and flow cytometry analysis. DLC2 and DLC3 overexpression inhibited proliferation and induced apoptosis in A549 cells. To the best of our knowledge, the current study was the first to investigate the expression level and prognostic values of DLC2 and DLC3 in NSCLC. The results indicated that DLC1 DLC2 and DLC3 serve specific roles in the occurrence and development of NSCLC, and may be considered as potential prognostic indicators in NSCLC. D.A. Spandidos 2019-06 2019-04-10 /pmc/articles/PMC6522875/ /pubmed/31059015 http://dx.doi.org/10.3892/mmr.2019.10146 Text en Copyright: © Sun et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Sun, Li
Sun, Jing
Song, Jun-Ding
High expression of DLC family proteins predicts better prognosis and inhibits tumor progression in NSCLC
title High expression of DLC family proteins predicts better prognosis and inhibits tumor progression in NSCLC
title_full High expression of DLC family proteins predicts better prognosis and inhibits tumor progression in NSCLC
title_fullStr High expression of DLC family proteins predicts better prognosis and inhibits tumor progression in NSCLC
title_full_unstemmed High expression of DLC family proteins predicts better prognosis and inhibits tumor progression in NSCLC
title_short High expression of DLC family proteins predicts better prognosis and inhibits tumor progression in NSCLC
title_sort high expression of dlc family proteins predicts better prognosis and inhibits tumor progression in nsclc
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6522875/
https://www.ncbi.nlm.nih.gov/pubmed/31059015
http://dx.doi.org/10.3892/mmr.2019.10146
work_keys_str_mv AT sunli highexpressionofdlcfamilyproteinspredictsbetterprognosisandinhibitstumorprogressioninnsclc
AT sunjing highexpressionofdlcfamilyproteinspredictsbetterprognosisandinhibitstumorprogressioninnsclc
AT songjunding highexpressionofdlcfamilyproteinspredictsbetterprognosisandinhibitstumorprogressioninnsclc